NO309427B1 - Modifiserte oligodeoksyribonukleotider, preparat for behandling eller profylakse av virusinfeksjoner, anvendelse av forbindelsene til fremstilling av preparatene, samt mellomprodukter for fremstilling av forbindelsene - Google Patents

Modifiserte oligodeoksyribonukleotider, preparat for behandling eller profylakse av virusinfeksjoner, anvendelse av forbindelsene til fremstilling av preparatene, samt mellomprodukter for fremstilling av forbindelsene Download PDF

Info

Publication number
NO309427B1
NO309427B1 NO940310A NO940310A NO309427B1 NO 309427 B1 NO309427 B1 NO 309427B1 NO 940310 A NO940310 A NO 940310A NO 940310 A NO940310 A NO 940310A NO 309427 B1 NO309427 B1 NO 309427B1
Authority
NO
Norway
Prior art keywords
group
formula
oxygen atom
atom
compound
Prior art date
Application number
NO940310A
Other languages
English (en)
Norwegian (no)
Other versions
NO940310D0 (no
NO940310L (no
Inventor
Hidehiko Furukawa
Kenji Momota
Hitoshi Hotoda
Makoto Koizumi
Masakatsu Kaneko
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of NO940310D0 publication Critical patent/NO940310D0/no
Publication of NO940310L publication Critical patent/NO940310L/no
Publication of NO309427B1 publication Critical patent/NO309427B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/336—Modified G
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
NO940310A 1993-01-29 1994-01-28 Modifiserte oligodeoksyribonukleotider, preparat for behandling eller profylakse av virusinfeksjoner, anvendelse av forbindelsene til fremstilling av preparatene, samt mellomprodukter for fremstilling av forbindelsene NO309427B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP1350993 1993-01-29
JP13557393 1993-06-07
JP13851793 1993-06-10

Publications (3)

Publication Number Publication Date
NO940310D0 NO940310D0 (no) 1994-01-28
NO940310L NO940310L (no) 1994-08-01
NO309427B1 true NO309427B1 (no) 2001-01-29

Family

ID=27280283

Family Applications (1)

Application Number Title Priority Date Filing Date
NO940310A NO309427B1 (no) 1993-01-29 1994-01-28 Modifiserte oligodeoksyribonukleotider, preparat for behandling eller profylakse av virusinfeksjoner, anvendelse av forbindelsene til fremstilling av preparatene, samt mellomprodukter for fremstilling av forbindelsene

Country Status (19)

Country Link
US (2) US5674856A (ko)
EP (1) EP0611075B1 (ko)
KR (1) KR100318796B1 (ko)
CN (2) CN1039014C (ko)
AT (1) ATE146479T1 (ko)
AU (1) AU670154B2 (ko)
CA (1) CA2114355A1 (ko)
CZ (1) CZ287050B6 (ko)
DE (1) DE69401136T2 (ko)
DK (1) DK0611075T3 (ko)
ES (1) ES2098866T3 (ko)
FI (1) FI111265B (ko)
GR (1) GR3022821T3 (ko)
HK (2) HK1000191A1 (ko)
HU (1) HU222834B1 (ko)
IL (1) IL108467A (ko)
NO (1) NO309427B1 (ko)
NZ (2) NZ250795A (ko)
RU (1) RU2111971C1 (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2114355A1 (en) * 1993-01-29 1994-07-30 Hidehiko Furukawa Modified oligodeoxyribonucleotides, their preparation and their therapeutic use
US6291438B1 (en) 1993-02-24 2001-09-18 Jui H. Wang Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use
CN1060177C (zh) * 1997-06-28 2001-01-03 中国科学院上海生物化学研究所 3′－单磷酸化寡核苷酸
GB9823646D0 (en) 1997-12-19 1998-12-23 Brax Genomics Ltd Compounds for mass spectrometry
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
DE10041809A1 (de) * 2000-08-25 2002-03-07 Giesing Michael Arrays immobilisierter Biomoleküle, deren Herstellung und Verwendung
US7205399B1 (en) 2001-07-06 2007-04-17 Sirna Therapeutics, Inc. Methods and reagents for oligonucleotide synthesis
US9394167B2 (en) 2005-04-15 2016-07-19 Customarray, Inc. Neutralization and containment of redox species produced by circumferential electrodes
US20070065877A1 (en) * 2005-09-19 2007-03-22 Combimatrix Corporation Microarray having a base cleavable succinate linker
WO2011071078A1 (ja) * 2009-12-08 2011-06-16 国立大学法人岐阜大学 芳香族化合物、並びに、それを用いたオリゴヌクレオチド誘導体合成用修飾担体、オリゴヌクレオチド誘導体及びオリゴヌクレオチド構築物
CN102766183B (zh) * 2011-05-05 2016-09-14 中国人民解放军军事医学科学院毒物药物研究所 具有抗hiv-1融合活性的修饰的核酸结构
CN116496335B (zh) * 2023-03-21 2024-03-08 中国药科大学 一种修饰核苷酸及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173356B1 (en) * 1980-02-29 1990-09-19 University Patents, Inc. Process for preparing modified inorganic polymers
US4849513A (en) * 1983-12-20 1989-07-18 California Institute Of Technology Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups
FR2568254B1 (fr) * 1984-07-25 1988-04-29 Centre Nat Rech Scient Application d'oligonucleotides lies a un agent intercalant, notamment a titre de medicament
US5252760A (en) * 1985-03-28 1993-10-12 Chiron Corporation Method of using colored phosphorylating reagents
DE3751468T2 (de) * 1986-10-30 1996-02-29 Daicel Chem Verfahren zur herstellung von oligonukleotiden und verbindungen zur bildung hochmolekularer schutzgruppen.
ATE87932T1 (de) * 1986-12-02 1993-04-15 Centre Nat Rech Scient Alpha-oligonukleotide.
US5276019A (en) * 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US4904582A (en) * 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
WO1990012022A1 (en) * 1989-03-31 1990-10-18 University Patents, Inc. Polynucleotide phosphorodithioates as therapeutic agents for retroviral infections
KR930702374A (ko) * 1990-11-20 1993-09-08 가와무라 요시부미 안티 센스 핵산 유도체
US5672697A (en) * 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
US5220003A (en) * 1991-03-29 1993-06-15 The Regents Of The University Of California Process for the synthesis of 2',3'-dideoxynucleosides
JP3061659B2 (ja) * 1991-08-01 2000-07-10 ヤマサ醤油株式会社 ２−｛２−（モノメトキシトリチルオキシ）エチルチオ｝エチル基および該基の使用法
US5646261A (en) * 1992-01-22 1997-07-08 Hoechst Aktiengesellschaft 3'-derivatized oligonucleotide analogs with non-nucleotidic groupings, their preparation and use
IL104461A (en) * 1992-01-22 2001-05-20 Hoechst Ag Analogs of oligonucleotide, their preparation and pharmaceutical preparations containing them
CA2114355A1 (en) * 1993-01-29 1994-07-30 Hidehiko Furukawa Modified oligodeoxyribonucleotides, their preparation and their therapeutic use
JPH09208729A (ja) * 1996-02-02 1997-08-12 Sekisui Chem Co Ltd 帯電防止プラスチックプレートもしくはシートの製造方法

Also Published As

Publication number Publication date
FI940425A (fi) 1994-11-04
IL108467A (en) 1999-09-22
HK1016151A1 (en) 1999-10-29
DE69401136D1 (de) 1997-01-30
US5807837A (en) 1998-09-15
US5674856A (en) 1997-10-07
CN1098107A (zh) 1995-02-01
EP0611075A1 (en) 1994-08-17
NZ250795A (en) 1997-04-24
KR940018394A (ko) 1994-08-16
NO940310D0 (no) 1994-01-28
CN1193013A (zh) 1998-09-16
DE69401136T2 (de) 1997-07-10
IL108467A0 (en) 1994-04-12
HUT66266A (en) 1994-10-28
ES2098866T3 (es) 1997-05-01
KR100318796B1 (ko) 2002-06-20
HK1000191A1 (en) 1998-01-27
RU2111971C1 (ru) 1998-05-27
FI111265B (fi) 2003-06-30
NZ280616A (en) 1997-04-24
AU670154B2 (en) 1996-07-04
AU5473194A (en) 1994-08-04
DK0611075T3 (da) 1997-07-07
CA2114355A1 (en) 1994-07-30
GR3022821T3 (en) 1997-06-30
NO940310L (no) 1994-08-01
EP0611075B1 (en) 1996-12-18
CZ19094A3 (en) 1994-12-15
HU222834B1 (hu) 2003-11-28
FI940425A0 (fi) 1994-01-28
CN1065238C (zh) 2001-05-02
HU9400246D0 (en) 1994-05-30
CN1039014C (zh) 1998-07-08
ATE146479T1 (de) 1997-01-15
CZ287050B6 (en) 2000-08-16

Similar Documents

Publication Publication Date Title
US5512668A (en) Solid phase oligonucleotide synthesis using phospholane intermediates
US5695979A (en) Inhibition of reverse transcriptase by phosphorodithioates
AU720472B2 (en) Novel bicyclonucleoside and oligonucleotide analogue
JP5689054B2 (ja) Ｒｎａ化学合成方法
US5883237A (en) Oligonucleotides having Rp and Sp linkages at predetermined locations
US8138330B2 (en) Process for the synthesis of oligonucleotides
US8901289B2 (en) Preparation of nucleotide oligomer
US5646267A (en) Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues
US20030105309A1 (en) Novel bicyclonucleoside and oligonucleotide analogue
WO2002018388A1 (fr) Analogues de nucleosides et derives d'oligonucleotides renfermant ces analogues
US5623068A (en) Synthesis of DNA using substituted phenylacetyl-protected nucleotides
AU716391B2 (en) Solid phase synthesis of oligonucleotides
NO309427B1 (no) Modifiserte oligodeoksyribonukleotider, preparat for behandling eller profylakse av virusinfeksjoner, anvendelse av forbindelsene til fremstilling av preparatene, samt mellomprodukter for fremstilling av forbindelsene
JPH0787982A (ja) 修飾オリゴデオキシリボヌクレオチド
JPH09503494A (ja) カーバメートヌクレオシド間結合を有するビルディングブロックおよびそれから誘導される新規なオリゴヌクレオチド
WO2022064908A1 (ja) 核酸オリゴマーの製造方法
AU659078B2 (en) Polynucleotide phosphorodithioates as therapeutic agents for retroviral infections
Filichev et al. Synthesis of a Thymidine Dimer Containing a Tetrazole‐2, 5‐diyl Internucleosidic Linkage and Its Insertion into Oligodeoxynucleotides
US7166718B2 (en) Calix[4]arene-nucleoside and calix[4]oligonucleotide hybrids
Jeong et al. Synthesis and hybridization property of sugar and phosphate linkage modified oligonucleotides
WO1999021874A1 (fr) Oligodesoxyribonucleotides contenant un nucleoside modifie et autre
JP3911703B2 (ja) アンチセンス核酸同族体
JPH0892275A (ja) 修飾オリゴデオキシリボヌクレオチド
FR2612930A1 (fr) Sondes oligonucleotidiques a
JP2000505081A (ja) オリゴヌクレオチドｎ３’→ｐ５’ホスホルアミデートの固相合成